Kach et al. [62] reported that two novel non-steroidal and highly selective GR modulators, CORT118335 and CORT108297, can block GR activity in PC and slow CRPC progression in vivo, thereby demonstrating the therapeutic potential for GR-expressing CRPC. The gene discussed is NR3C1; the disease is pachyonychia congenita.